Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

Highlights from ASCO 2021

OncoAlert and ecancer ASCO roundup - Day 3

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC